Key Metrics
5.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.84
5-Year SI
5-year SI
- N/A 2-year SI
- 0.85 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.51
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
27%
4 to 6 months
70%
7 to 9 months
3%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
DOAJ -
SJR
Topics Covered
- Breast cancer
- Overall survival
- Metastatic breast cancer
- Cross-sectional study
- Breast cancer screening
- Trastuzumab
- Triple-negative breast cancer
- Pathological response
- Molecular pathology
- Quality of life
- Mastectomy
- Ataxia telangiectasia mutated
- Breast cancer cells
- Eribulin
- Hormone therapy
- Progesterone receptor
- Axillary ultrasound
- Standard therapy
- Immunohistochemistry
- Breast examination
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2836 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2836 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Breast Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Intermediate Filaments in Breast Cancer Progression, and Potential Biomarker for Cancer Therapy: A Narrative Review.
- 1 Oct 24
- Breast cancer (Dove Medical Press)
-
Full paper
Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram
- 1 Oct 24
- Breast Cancer: Targets and Therapy
-
Full paper
The Potential Role of SNRPD1 Stabilized by IGF2BP2 in the Progression of Triple-Negative Breast Cancer
- 1 Oct 24
- Breast Cancer: Targets and Therapy
-
Full paper
Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients.
- 1 Sep 24
- Breast cancer (Dove Medical Press)
-
Full paper
Unraveling the Role of PCDH9 in Breast Cancer and Identifying Therapeutic Strategies for PCDH9-Deficient Tumors.
- 1 Sep 24
- Breast cancer (Dove Medical Press)
-
Full paper
A Prognostic Risk Signature of Two Autophagy-Related Genes for Predicting Triple-Negative Breast Cancer Outcomes.
- 1 Sep 24
- Breast cancer (Dove Medical Press)
Scite analysis
Powered by scite_
519 articles received 6.7k citations see all
- 262 Supporting
- 6,160 Mentioning
- 45 Contrasting
Editorial notices
- 4 Retractions
- 0 Withdrawals
- 0 Corrections
- 5 Errata
- 0 Expression of Concern
FAQs
How long has Breast Cancer: Targets and Therapy been actively publishing?
Breast Cancer: Targets and Therapy has been in operation since 2009 till date.
What is the publishing frequency of Breast Cancer: Targets and Therapy ?
Breast Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Breast Cancer: Targets and Therapy publish last years ?
In 2023, Breast Cancer: Targets and Therapy published 79 articles.
What is the eISSN & pISSN for Breast Cancer: Targets and Therapy ?
For Breast Cancer: Targets and Therapy,eISSN is 1179-1314 and pISSN is1179-1314.
What is Citescore for Breast Cancer: Targets and Therapy ?
Citescore for Breast Cancer: Targets and Therapy is 5.9.
What is SNIP score for Breast Cancer: Targets and Therapy ?
SNIP score for Breast Cancer: Targets and Therapy is 1.51.
What is the SJR for Breast Cancer: Targets and Therapy ?
SJR for Breast Cancer: Targets and Therapy is Q1.
Who is the publisher of Breast Cancer: Targets and Therapy ?
DOVE MEDICAL PRESS LTD is the publisher of Breast Cancer: Targets and Therapy.